News Novo's Saxenda label to include cardio data Label will reflect heart benefit seen in LEADER trial.
News Oral insulin could still be a reality, says Novo Nordisk Last October Novo Nordisk announced that it had shelved plans to bring the world’s first oral insulin to market .
News Biotech vTv believes small molecule GLP-1 pill can take on b... Pill could be effective in diabetes, with fewer GI effects.
News Novo hopes data will boost new insulin in US and Germany Novo Nordisk hopes that new data supporting the cardiovascular and glycaemic safety of its Tresiba long-acting insulin will prove a game-changer in the US.
Views & Analysis ADA preview: cardio data in diabetes, drug costs and healthc... Invokana data could suggest cardio benefit for SGLT2 class.
Views & Analysis Novo Nordisk: survival of the fittest applies in diabetes an... Diabetes specialist Novo Nordisk is feeling the heat from increasingly price conscious US payers.
News Relief for AZ as Truqap hits the spot in prostate cancer After a disappointing result with Truqap in triple-negative breast cancer, AstraZeneca chalks up a win in prostate cancer
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
